Form 4: Vericel Corp Director Steven Gilman Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Steven Gilman exercised stock options and sold shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 18, 2024, Steven Gilman, a director of Vericel Corp, exercised stock options to acquire 5,834 shares of common stock at a price of $13.05 per share.
• Simultaneously, Gilman sold 5,834 shares of common stock at a price of $45.54 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2024.
• Following these transactions, Gilman directly owns 11,000 shares of Vericel Corp common stock and holds options to purchase 11,666 additional shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative prospects for the company.

Positives

• The execution of a 10b5-1 trading plan allows insiders to sell shares without concerns about insider trading, as the plan is pre-arranged.

Industry Context

This filing is a routine disclosure of insider transactions. It is common for corporate insiders to use 10b5-1 plans to manage their stock holdings and avoid potential accusations of insider trading.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies.
• The use of 10b5-1 trading plans is a standard practice among corporate executives to manage their stock sales in compliance with SEC regulations.
• Comparable companies such as Organogenesis Holdings Inc. and MiMedx Group, Inc. also have executives who utilize 10b5-1 plans.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.

Key Dates